EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Prostatype Genomics AB's Enterprise Value is kr21.68 Mil.
Prostatype Genomics AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr-37.24 Mil. Therefore, Prostatype Genomics AB's EV-to-FCF for today is -0.58.
The historical rank and industry rank for Prostatype Genomics AB's EV-to-FCF or its related term are showing as below:
OSTO:PROGEN'
s EV-to-FCF Range Over the Past 10 Years
Min: -102.94 Med: -4.45 Max: 0.35
Current: -0.65
During the past 7 years, the highest EV-to-FCF of Prostatype Genomics AB was 0.35. The lowest was -102.94. And the median was -4.45.
OSTO:PROGEN's EV-to-FCF is ranked worse than 100% of 97
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.51
vs OSTO:PROGEN: -0.65
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prostatype Genomics AB (OSTO:PROGEN) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prostatype Genomics AB's PE Ratio (TTM) for today is calculated as:
Prostatype Genomics AB's share price for today is kr0.43.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-1.050.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:PROGEN vs TMO, DHR, IDXX: EV-to-FCF Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's EV-to-FCF falls into.
Prostatype Genomics AB's current Enterprise Value is kr21.68 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr-37.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB (OSTO:PROGEN) has a EV-to-FCF of -0.58 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Prostatype Genomics AB and its competitors. According to the industry distribution chart, Prostatype Genomics AB ranks #999999 out of 97 companies in the Medical Diagnostics & Research industry.
Is Prostatype Genomics AB's EV-to-FCF too high?
Prostatype Genomics AB's current EV-to-FCF is -0.58. Based on the distribution chart, Prostatype Genomics AB ranks #999999 out of 97 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #999999 out of 97 companies for EV-to-FCF. This places Prostatype Genomics AB in the lower half of its industry. The industry median EV-to-FCF is 22.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.51, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Prostatype Genomics AB and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostatype Genomics AB's current EV-to-FCF is -0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.11, compared to a current price of kr0.43 — trading 290.9% above its estimated fair value. The current EV-to-FCF is -0.58. Prostatype Genomics AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current EV-to-FCF is -0.58 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.43 is trading 290.9% above its estimated GF Value™ of kr0.11.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
EV-to-FCF: -0.58
GF Value™: kr0.11 vs. price of kr0.43 (290.9% above fair value)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score
Get the complete analysis for OSTO:PROGEN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
